Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228347 | 0.99 | HRH3 (0.37) | HRH3BRD4CREBBPTERTALDH1A1 | |
| SCHEMBL14113768 | 0.96 | HRH3 (0.41) | HRH3BRD4CREBBPTERTKCNH2 | |
| SCHEMBL9922423 | 0.93 | HTT (0.41) | BRD4CREBBPMAPT | |
| SCHEMBL12160785 | 0.91 | PSEN1 (0.42) | HRH3TERTALDH1A1MAPTP2RY12 | |
| SCHEMBL9922424 | 0.90 | P2RY12 (0.42) | HRH3TERTKCNH2P2RY12 | |
| SCHEMBL12177249 | 0.90 | BRD4 (0.38) | HRH3BRD4CREBBPTERTALDH1A1 | |
| SCHEMBL13638507 | 0.90 | BRD4 (0.38) | HRH3BRD4CREBBPTERTALDH1A1 | |
| SCHEMBL9922849 | 0.90 | HRH3 (0.37) | HRH3TERTALDH1A1MAPTKCNH2 | |
| SCHEMBL9922278 | 0.89 | HRH3 (0.36) | HRH3BRD4CREBBPTERTKCNH2 | |
| SCHEMBL12177620 | 0.89 | BRD4 (0.37) | BRD4CREBBPALDH1A1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | HRH3 2498/4885BRD4 3757/4885CREBBP 3537/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | HRH3 1858/4885BRD4 3064/4885CREBBP 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.